{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:29:55Z","timestamp":1780774195132,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Triptans are the first-line option for the acute treatment of migraine attacks; however, triptans are contraindicated in people with certain underlying cardiovascular risk factors and are associated with inadequate efficacy or poor tolerability in some individuals. Ubrogepant is an oral calcitonin gene\u2013related peptide receptor antagonist approved for the acute treatment of migraine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This post hoc analysis of the phase 3 ACHIEVE trials examined the impact of ubrogepant on the Functional Disability Scale (FDS), satisfaction with medication, and Patient Global Impression of Change (PGIC) in participants who were self-reported triptan insufficient responders (TIRs), defined as those who are unable to take triptans due to contraindications, tolerability issues, or insufficient efficacy. Responder definitions for the FDS, satisfaction measures, and PGIC were based on qualitative interpretation of the respective response options for the pooled ubrogepant 50\u00a0mg and placebo groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the pooled analysis population (<jats:italic>n<\/jats:italic>\u2009=\u20091799), 451 (25%) participants were TIRs, with most (80%) reporting insufficient efficacy with triptan use. A significantly higher proportion of TIRs treated with ubrogepant vs placebo reported being able to function normally from 2 to 8\u00a0h post dose (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Notably, significance was demonstrated at the time of the primary outcome assessments (2\u00a0h post dose), where rates of normal function were 38% for ubrogepant vs 29% for placebo (<jats:italic>P<\/jats:italic>\u2009=\u20090.048). A greater proportion of TIRs in the ubrogepant arm vs the placebo arm were satisfied with treatment at 2 (33% vs 21%,<jats:italic>P<\/jats:italic>\u2009=\u20090.006) and 24\u00a0h (58% vs 28%,<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and indicated that their migraine improved at 2\u00a0h vs placebo (30% vs 18%,<jats:italic>P<\/jats:italic>\u2009=\u20090.006). Results were generally similar in the insufficient efficacy subpopulation of TIRs as in the overall TIRs group. Ubrogepant was safe and well tolerated in TIRs, with no new safety signals identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In people with migraine who are TIRs, individuals treated with ubrogepant had favorable 2-h outcomes, as measured by the FDS, satisfaction with medication, and PGIC, compared with placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>ClinicalTrials.gov:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02828020\">NCT02828020<\/jats:ext-link>(ACHIEVE I), registered July 11, 2016;<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02867709\">NCT02867709<\/jats:ext-link>(ACHIEVE II), registered August 16, 2016.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s10194-022-01419-7","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T11:03:53Z","timestamp":1650884633000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials"],"prefix":"10.1186","volume":"23","author":[{"given":"Richard B.","family":"Lipton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi B. Halker","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Revicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3138-5623","authenticated-orcid":false,"given":"Anand R.","family":"Shewale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan E.","family":"Lateiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Dodick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"1419_CR1","doi-asserted-by":"crossref","unstructured":"Feigin VL, Vos T, Alahdab F, Amit AML, B\u00e4rnighausen TW, Beghi E et al (2021) Burden of neurological disorders across the US from 1990\u20132017: a global burden of disease study. JAMA Neurol 78(2):165\u2013176.","DOI":"10.1001\/jamaneurol.2020.4152"},{"key":"1419_CR2","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators","year":"2017","unstructured":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1211\u20131259","journal-title":"Lancet"},{"key":"1419_CR3","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013211","DOI":"10.1177\/0333102417738202"},{"key":"1419_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","volume":"31","author":"AM Blumenfeld","year":"2011","unstructured":"Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A et al (2011) Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 31:301\u2013315","journal-title":"Cephalalgia"},{"key":"1419_CR5","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1111\/j.1526-4610.2012.02223.x","volume":"52","author":"DC Buse","year":"2012","unstructured":"Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC et al (2012) Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention study. Headache 52:1456\u20131470","journal-title":"Headache"},{"key":"1419_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society (2019) The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 59:1\u201318","journal-title":"Headache"},{"key":"1419_CR7","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1111\/head.13588","volume":"59","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Munjal S, Buse DC, Alam A, Fanning KM, Reed ML et al (2019) Unmet acute treatment needs from the 2017 Migraine in America Symptoms and Treatment Study. Headache 59:1310\u20131323","journal-title":"Headache"},{"key":"1419_CR8","doi-asserted-by":"crossref","unstructured":"Roberto G, Piccinni C, D\u2019Alessandro R, Poluzzi E (2014) Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database. Cephalalgia 34:5\u201313","DOI":"10.1177\/0333102413499649"},{"key":"1419_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s10194-017-0811-5","volume":"18","author":"S Benemei","year":"2017","unstructured":"Benemei S, Cortese F, Labastida-Ram\u00edrez A, Marchese F, Pellesi L, Romoli M et al (2017) Triptans and CGRP blockade - impact on the cranial vasculature. J Headache Pain 18:103","journal-title":"J Headache Pain"},{"key":"1419_CR10","doi-asserted-by":"crossref","unstructured":"Gelfand AA, Goadsby PJ (2012) A neurologist\u2019s guide to acute migraine therapy in the emergency room. Neurohospitalist 2:51\u201359","DOI":"10.1177\/1941874412439583"},{"key":"1419_CR11","unstructured":"Imitrex [package insert] (2017) Research Triangle Park, NC: GlaxoSmithKline"},{"key":"1419_CR12","doi-asserted-by":"publisher","first-page":"215013272096368","DOI":"10.1177\/2150132720963680","volume":"11","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Shewale AS, Lipton RB, Baum SJ, Marcus SC, Silberstein SD et al (2020) Migraine patients with cardiovascular disease and contraindications: an analysis of real-world claims data. J Prim Care Community Health 11:2150132720963680","journal-title":"J Prim Care Community Health"},{"key":"1419_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-020-01110-9","volume":"21","author":"L Lombard","year":"2020","unstructured":"Lombard L, Farrar M, Ye W, Kim Y, Cotton S, Buchanan AS et al (2020) A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J Headache Pain 21:41","journal-title":"J Headache Pain"},{"key":"1419_CR14","doi-asserted-by":"crossref","unstructured":"Marcus SC, Shewale AR, Silberstein SD, Lipton RB, Young WB, Viswanathan HN et al (2020) Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response. Cephalalgia 40(7):639\u2013649","DOI":"10.1177\/0333102420915167"},{"key":"1419_CR15","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S\u00a0(2017) Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 97:553\u2013622","DOI":"10.1152\/physrev.00034.2015"},{"key":"1419_CR16","unstructured":"Ubrelvy [package insert] (2021) Madison, NJ: Allergan USA, Inc."},{"key":"1419_CR17","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM et al (2019) Ubrogepant for the treatment of migraine. N Engl J Med 381:2230\u20132241","journal-title":"N Engl J Med"},{"key":"1419_CR18","doi-asserted-by":"crossref","unstructured":"Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A et al (2019) Effect of ubrogepant versus placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA 322:1887\u20131898","DOI":"10.1001\/jama.2019.16711"},{"key":"1419_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/head.13682","volume":"60","author":"J Ailani","year":"2020","unstructured":"Ailani J, Lipton RB, Hutchinson S, Knievel K, Lu K, Butler M et al (2020) Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache 60:141\u2013152","journal-title":"Headache"},{"key":"1419_CR20","doi-asserted-by":"crossref","unstructured":"Curto M, Capi M, Cipolla F, Cisale GY, Martelletti P, Lionetto L (2020) Ubrogepant for the treatment of migraine. Expert Opin Pharmacother 21:755\u2013759","DOI":"10.1080\/14656566.2020.1721462"},{"key":"1419_CR21","doi-asserted-by":"crossref","unstructured":"Do TP, Guo S, Ashina M (2019) Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain 20:37","DOI":"10.1186\/s10194-019-0974-3"},{"key":"1419_CR22","doi-asserted-by":"crossref","unstructured":"Singh A, Gupta D, Sahoo AK (2020) Acute migraine: Can the new drugs clinically outpace? SN Compr Clin Med 2:1132\u20131138","DOI":"10.1007\/s42399-020-00390-1"},{"key":"1419_CR23","doi-asserted-by":"crossref","unstructured":"Lucas C, Aly S, Touboul C, Sellami R, Guillaume X, Garcia G (2020) Patient-reported outcome in two chronic diseases: a comparison of quality of life and response profiles in severe migraine and severe asthma. Patient Relat Outcome Meas 11:27\u201337","DOI":"10.2147\/PROM.S222597"},{"key":"1419_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/head.14067","volume":"61","author":"CR Houts","year":"2021","unstructured":"Houts CR, McGinley JS, Nishida TK, Buse DC, Wirth RJ, Dodick DW et al (2021) Systematic review of outcomes and endpoints in acute migraine clinical trials. Headache 61:263\u2013275","journal-title":"Headache"},{"key":"1419_CR25","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/head.13766","volume":"60","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Lipton RB, Ailani J, Halker Singh RB, Shewale AR, Zhao S et al (2020) Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials ACHIEVE I and II. Headache 60:686\u2013700","journal-title":"Headache"},{"key":"1419_CR26","doi-asserted-by":"crossref","unstructured":"Ailani J, Burch RC, Robbins MS (2021) The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache 61:1021\u20131039","DOI":"10.1111\/head.14153"},{"key":"1419_CR27","doi-asserted-by":"crossref","unstructured":"Katic BJ, Rajagopalan S, Ho TW, Chen YT, Hu XH (2011) Triptan persistency among newly initiated users in a pharmacy claims database. Cephalalgia 31:488\u2013500","DOI":"10.1177\/0333102410383058"},{"key":"1419_CR28","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/head.12404","volume":"54","author":"AJ Messali","year":"2014","unstructured":"Messali AJ, Yang M, Gillard P, Tsai K, Tepper SJ, Bloudek LM et al (2014) Treatment persistence and switching in triptan users: a systematic literature review. Headache 54:1120\u20131130","journal-title":"Headache"},{"key":"1419_CR29","doi-asserted-by":"crossref","unstructured":"Blumenfeld AM, Goadsby PJ, Dodick DW, Hutchinson S, Liu C, Finnegan M et al (2021) Efficacy of ubrogepant based on prior exposure and response to triptans: a post hoc analysis. Headache 61:422\u2013429","DOI":"10.1111\/head.14089"},{"key":"1419_CR30","doi-asserted-by":"crossref","unstructured":"Bangdiwala SI, Bhargava A, O\u2019Connor DP, Robinson TN, Michie S, Murray DM et al (2016) Statistical methodologies to pool across multiple intervention studies. Transl Behav Med 6:228\u2013235","DOI":"10.1007\/s13142-016-0386-8"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01419-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01419-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01419-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T14:48:10Z","timestamp":1700491690000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01419-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1419"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01419-7","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"assertion":[{"value":"7 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ACHIEVE I and ACHIEVE II trials were conducted in conformance with the Declaration of Helsinki principles, or US laws and regulations, whichever afforded the greater protection to the individual. Trial protocols were approved by each individual research center\u2019s institutional review board. Written informed consent was obtained from all participants prior to initiation of trial procedures. All authors had full access to all data from both studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RBL has received research support from the National Institutes of Health, the FDA, and the National Headache Foundation. He serves as consultant, advisory board member, or has received honoraria or research support from AbbVie\/Allergan, Amgen, Biohaven, Dr. Reddy\u2019s Laboratories (Promius), electroCore, Eli Lilly, GlaxoSmithKline, Lundbeck, Merck, Novartis, Teva, Vector, and Vedanta Research. He receives royalties from <i>Wolff\u2019s Headache<\/i>, 8th edition (Oxford University Press, 2009), and Informa. He holds stock\/options in Biohaven, Ctrl M, and Manistee.RBHS reports honoraria for advisory boards from Impel, Supernus, and Teva, and grants for research support from Amgen and Eli Lilly.DAR received research support from Allergan and Amgen, and served as a consultant for AbbVie, Allergan, and Amgen.DWD reports the following conflicts: Consulting: Amgen, Atria, Cerecin, Cooltech, Ctrl M, Allergan, Abbvie, Biohaven, GSK, Lundbeck, Eli Lilly, Novartis, Impel, Satsuma, Theranica, WL Gore, Genentech, Nocira, Perfood, Praxis, AYYA Biosciences, Revance. Honoraria: American Academy of Neurology, Headache Cooperative of the Pacific, MF Med Ed Research, Biopharm Communications, CEA Group Holding Company (Clinical Education Alliance LLC), Teva (speaking), Amgen (speaking), Eli Lilly (speaking), Lundbeck (speaking), Vector Psychometric Group, Clinical Care Solutions, CME Outfitters, Curry Rockefeller Group, DeepBench, Global Access Meetings, KLJ Associates, Academy for Continued Healthcare Learning, Majallin LLC, Medlogix Communications, Medica Communications LLC, MJH Lifesciences, Miller Medical Communications, WebMD Health\/Medscape, Wolters Kluwer, Oxford University Press, Cambridge University Press. Non-profit board membership: American Brain Foundation, American Migraine Foundation, ONE Neurology, Precon Health Foundation, International Headache Society Global Patient Advocacy Coalition, Atria Health Collaborative, Domestic Violence HOPE Foundation\/Panfila. Research Support: Department of Defense, National Institutes of Health, Henry Jackson Foundation, Sperling Foundation, American Migraine Foundation, Patient Centered Outcomes Research Institute (PCORI). Stock Options\/Shareholder\/Patents\/Board of Directors: Ctrl M (options), Aural analytics (options), ExSano (options), Palion (options), Healint (options), Theranica (options), Second Opinion\/Mobile Health (options), Epien (options\/Board), Nocira (options), Matterhorn (shares\/Board), Ontologics (shares\/Board), King-Devick Technologies (options\/Board), Precon Health (options\/Board), AYYA Biosciences (options), Axon Therapeutics (options\/Board), Cephalgia Group (options\/Board), Atria Health (options\/employee). Patent 17189376.1\u20131466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis.ARS is an employee of AbbVie, and may hold AbbVie stock.SZ and JEL were employees of AbbVie at the time of study conduct and may hold AbbVie stock.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}